Back to Search Start Over

Impact of Resveratrol on Glucose Control, Hippocampal Structure and Connectivity, and Memory Performance in Patients with Mild Cognitive Impairment

Authors :
Ariane Schnelle
Jan Philipp Schuchardt
A. Veronica Witte
Andreas Hahn
Ulrike Grittner
Jens Bohlken
Theresa Köbe
Agnes Flöel
Johannes Pantel
Valentina A. Tesky
La Joie, Renaud
Source :
Frontiers in Neuroscience 11 (2017), Frontiers in Neuroscience
Publication Year :
2017
Publisher :
Frontiers Media SA, 2017.

Abstract

In healthy older adults, resveratrol supplementation has been shown to improve long-term glucose control, resting-state functional connectivity (RSFC) of the hippocampus, and memory function. Here, we aimed to investigate if these beneficial effects extend to individuals at high-risk for dementia, i.e., patients with mild cognitive impairment (MCI). In a randomized, double-blind interventional study, 40 well-characterized patients with MCI (21 females; 50–80 years) completed 26 weeks of resveratrol (200 mg/d; n = 18) or placebo (1,015 mg/d olive oil; n = 22) intake. Serum levels of glucose, glycated hemoglobin A1c and insulin were determined before and after intervention. Moreover, cerebral magnetic resonance imaging (MRI) (3T) (n = 14 vs. 16) was conducted to analyze hippocampus volume, microstructure and RSFC, and neuropsychological testing was conducted to assess learning and memory (primary endpoint) at both time points. In comparison to the control group, resveratrol supplementation resulted in lower glycated hemoglobin A1c concentration with a moderate effect size (ANOVARM p = 0.059, Cohen's d = 0.66), higher RSFC between right anterior hippocampus and right angular cortex (p < 0.001), and led to a moderate preservation of left anterior hippocampus volume (ANOVARM p = 0.061, Cohen's d = 0.68). No significant differences in memory performance emerged between groups. This proof-of-concept study indicates for the first-time that resveratrol intake may reduce glycated hemoglobin A1c, preserves hippocampus volume, and improves hippocampus RSFC in at-risk patients for dementia. Larger trials with longer intervention time should now determine if these benefits can be validated and extended to cognitive function. DFG/Fl 379-10/1 DFG/Fl 379-11/1 DFG/EXC/257 BMBF/FKZ 0315673A BMBF/01EO0801 BMBF/01GQ1424A BMBF/01GQ1420B

Details

ISSN :
1662453X
Volume :
11
Database :
OpenAIRE
Journal :
Frontiers in Neuroscience
Accession number :
edsair.doi.dedup.....7312a981e822c8014fe893e35bdfd331